When was Beijing Jiakesi drug development founded?

Beijing Jiakesi drug development was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Beijing Jiakesi drug development located?

Beijing Jiakesi drug development is headquartered in Beijing, China.

Who is the current CEO of Beijing Jiakesi drug development?

Wang Xiaojie of Beijing Jiakesi drug development.

Is Beijing Jiakesi drug development a funded company?

Beijing Jiakesi drug development is a funded company, having raised a total of $55M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 2016.

When was the latest funding round of Beijing Jiakesi drug development?

Beijing Jiakesi drug development's latest funding was a $***** Series C round on Aug 30, 2018, with participation from 3 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $98.7M in funding in 2026 to date.

Where does Beijing Jiakesi drug development rank among its competitors?

Beijing Jiakesi drug development ranks 4th amongst 274 active competitors, of which 111 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Lyell Immunopharma, which secured $100M in Jul, 2025.

Beijing Jiakesi drug development - 2026 Company Profile, Team, Funding & Competitors

Q: Who are the top competitors of Beijing Jiakesi drug development?

Beijing Jiakesi drug development's top competitors include Agios Pharmaceuticals, Hummingbird Bioscience and Lyell Immunopharma. Among them, Lyell Immunopharma secured the most recent funding round in July, 2025.

Beijing Jiakesi drug development is a public company based in Beijing (China), founded in 2015 by Wang Yinxiang. It operates as a Developer of small molecule based therapeutics for cancer treatment. Beijing Jiakesi drug development has raised $55M in funding from investors like Qiming Venture Partners, Lilly Asia Ventures and Hillhouse. The company has 274 active competitors, including 111 funded and 60 that have exited. Its top competitors include companies like Agios Pharmaceuticals, Hummingbird Bioscience and Lyell Immunopharma.

Company Details

Beijing Jiakesi is developing small molecule-based therapeutics for cancer treatment. The company's lead product candidate JAB-3068 is an anti-tumor small molecule which is in Phase 1 clinical trials. Other products of the company include JAB-3000, JAB-6000, JAB-8000 used against cancer which are in pre-clinical trials.

Website: jacobiopharma.com
Email ID: *****@jacobiopharma.com
Phone Number: +86 **********

Key Metrics

Founded Year

2015

Location

Beijing, China

Stage

Public

Total Funding

$55M in 3 rounds

Latest Funding Round

Series C, Aug 30, 2018, $*****

Investors

Qiming Venture Partners & 4 more

Ranked

4^th among 274 active competitors

Investment & Acquisitions

HebeCell

Similar Companies

Agios Pharmaceuticals & 361 more

Exit Details

Public

View Beijing Jiakesi drug development's full profile

Beijing Jiakesi drug development got listed on Dec 21, 2020.

Click here to take a look at Beijing Jiakesi drug development's IPO in detail

Beijing Jiakesi drug development has raised a total funding of $55M over 3 rounds. Its first funding round was on Feb 2016. Its latest funding round was a Series C round on Aug 30, 2018 for $*****. 3 investors participated in its latest round. Beijing Jiakesi drug development has 5 institutional investors.

Here is the list of recent funding rounds of Beijing Jiakesi drug development:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 30, 2018	7773855	Series C	7585788	1869820	8282440	6750991
2017	4656	Series B	2326	9986	7179	6433
Feb 2016	2605078	Series A	7927712	2932584	9438221	5220952

Access funding benchmarks and valuations. Sign up today!

View details of Beijing Jiakesi drug development's funding rounds and investors

The founders of Beijing Jiakesi drug development is Wang Yinxiang.

Here are the details of Beijing Jiakesi drug development's key team members:

Wang Yinxiang: Founder & Chairman of Beijing Jiakesi drug development.
Wang Xiaojie: CEO of Beijing Jiakesi drug development.
Contact Info: 1 email address

View details of Beijing Jiakesi drug development's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beijing Jiakesi drug development include Agios Pharmaceuticals, Hummingbird Bioscience and Lyell Immunopharma. Here is the list of Top 10 competitors of Beijing Jiakesi drug development, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Third Rock Ventures ... & 6 others	70/100
2nd	Hummingbird Bioscience 2015, Singapore (Singapore), Series C	Developer of antibody drugs for cancer treatment	$150M	OCTAVE Capital, GNTech Venture Capital & 23 others	68/100
3rd	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	66/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Octagon Capital Advisors, Qiming Venture Partners ... & 3 others	66/100
5th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Bayer & 19 others	65/100
6th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	64/100
7th	Accent Therapeutics 2017, Lexington (United States), Series C	Developing RNA-modifying protein therapeutics for cancer with significant unmet medical need	$178M	EcoR1, The Column Group & 10 others	62/100
8th	Fusion Pharmaceuticals 2014, Hamilton (Canada), Acquired	Developer of targeted alpha therapeutics for the treatment of cancers	$171M	Varian Medical Systems, Seroba Life Sciences ... & 16 others	62/100
9th	Bolt Biotherapeutics 2015, Redwood City (United States), Public	Developer of T-cell therapies for the treatment of cancer	$177M	Pivotal bioVenture Partners, Sofinnova Investments ... & 7 others	61/100
10th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	Boxer Capital, RA Capital Management & 19 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Beijing Jiakesi drug development's competitors? Click here to see the top ones

Beijing Jiakesi drug development has a total of 1 investment in HebeCell. Beijing Jiakesi drug development has not made any acquisitions as of now.

Here is the latest report on Beijing Jiakesi drug development's sector:

Free

Oncology - Sector Report

Edition: October, 2025 (81 Pages)

View all reports related to Beijing Jiakesi drug development

Media has covered Beijing Jiakesi drug development for a total of 14 events in the last 1 year, 7 of them have been about company updates and 1 about partnerships.